Methods and compositions for treeating proliferative diseases

Abstract

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

1 - 16 . (canceled) 
     
     
         17 . A method of treating a proliferative disease in an individual comprising administering to the individual:
 a) an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, and   b) an effective amount of at least one other chemotherapeutic agent, wherein said chemotherapeutic agent is selected from the group consisting of antimetabolites, platinum-based agents, alkylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkloids, proteasome inhibitors, macrolides, and topoisomerase inhibitors.   
     
     
         18 . The method according to  claim 17 , wherein said chemotherapeutic agent is an antimetabolite agent. 
     
     
         19 . The method according to  claim 18 , wherein said chemotherapeutic agent is a platinum-based agent. 
     
     
         20 . The method according to  claim 17 , wherein said chemotherapeutic agent is a tyrosine kinase inhibitor. 
     
     
         21 . The method according to  claim 17 , wherein the proliferative disease is cancer. 
     
     
         22 . The method according to  claim 17 , wherein the taxane is paclitaxel. 
     
     
         23 . The method according to  claim 22 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         24 . The method according to  claim 17 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         25 . The method according to  claim 17 , wherein the individual is a human. 
     
     
         26 . A method of treating a tumor in an individual comprising:
 a) a first therapy comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, and   b) a second therapy comprising radiation therapy, surgery, or combinations thereof.   
     
     
         27 . The method according to  claim 26 , wherein the taxane is paclitaxel. 
     
     
         28 . The method according to  claim 27 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         29 . The method according to  claim 26 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         30 . The method according to  claim 26 , wherein the individual is a human. 
     
     
         31 . A method of administering a composition comprising nanoparticles comprising a taxane and an albumin to an individual,
 wherein the nanoparticle composition is administered over a period of at least one month, wherein the interval between each administration is no more than about a week, and   wherein the dose of taxane in the composition at each administration is about 0.25% to about 25% of its maximum tolerated dose following a traditional dosing regime.   
     
     
         32 . The method according to  claim 31 , wherein said taxane is paclitaxel. 
     
     
         33 . The method according to  claim 32 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         34 . The method according to  claim 31 , wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. 
     
     
         35 . The method according to  claim 31 , wherein the individual is a human.